Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-NeoB plus capecitabine in GRPR-positive ER-positive HER2-negative metastatic breast cancer
NL-OMON59454Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AAA503 and capecitabine in breast cancer (3 arms), sponsored by Novartis. Primary endpoints: Safety and tolerability including dose-limiting toxicities and Preliminary antitumor activity. Started Apr 2024; status: completed.
02
Drugs
AAA503capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON59454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59454.